Incidence and Impacts of Inflammatory Bowel Diseases among Kidney Transplant Recipients: A Meta-Analysis

BACKGROUND: The incidence of inflammatory bowel diseases (IBD) and its significance in kidney transplant recipients is not well established. We conducted this systematic review and meta-analysis to assess the incidence of and complications from IBD in adult kidney transplant recipients. METHODS: Eligible articles were searched through Ovid MEDLINE, EMBASE, and the Cochrane Library from inception through April 2020. The inclusion criteria were adult kidney transplant patients with reported IBD. Effect estimates from the individual studies were extracted and combined using the fixed-effects model when I2 ≤ 50% and random-effects model when I2 > 50%. RESULTS: of 641 citations, a total of seven studies (n = 212) were included in the systematic review. The mean age was 46.2 +/- 6.9 years and up to 51.1% were male. The mean duration of follow-up was 57.8 +/- 16.8 months. The pooled incidence of recurrent IBD was 27.6% (95% CI, 17.7-40.5%; I2 0%) while the pooled incidence of de novo IBD was 18.8% (95% CI, 10.7-31.0%; I2 61.3%). The pooled incidence of post-transplant IBD was similar across subgroup analyses. Meta-regression analyses showed no association between the incidence of IBD and age, male sex, and follow-up duration. For post-transplant complications, the pooled incidence of post-transplant infection was 4.7% (95% CI, 0.5-33.3%; I2 73.7%). The pooled incidence of graft rejection and re-transplantation in IBD patients was 31.4% (95% CI, 14.1-56.1%; I2 76.9%) and 30.4% (95% CI, 22.6-39.5%; I2 0%). CONCLUSION: Recurrent and de novo IBD is common among kidney transplant recipients and may result in adverse outcomes.